Overview

Efficacy and Safety of JT001 (VV116) Compared With Paxlovid

Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of JT001 (VV116) Compared With Paxlovid for the Treatment of Coronavirus Disease 2019 (COVID-19) in Participants With Mild to Moderate COVID-19.
Phase:
Phase 3
Details
Lead Sponsor:
Vigonvita Life Sciences
Treatments:
Ritonavir